Henry Schein, Inc. announced the appointment of Frederick M. Lowery as chief executive officer, effective March 2, 2026. At that time, Lowery will also join the company’s board of directors. He will succeed Stanley M. Bergman, who will step down as chief executive officer after 35 years and continue to serve as chairman of the board.
Lowery most recently served as executive vice president and president, Laboratory Products and BioProduction at Thermo Fisher Scientific, where he led the Fisher Scientific distribution channel. His background includes experience in distribution, manufacturing, research and development, marketing, and sales. The company stated that his experience aligns with its business model and ongoing BOLD+1 strategic plan.
“I am honored to join Henry Schein at such a pivotal moment. This is an organization with immense potential to impact clinicians and patients, given its remarkable reputation for innovation, customer service, and partnership,” said Frederick M. Lowery. “I look forward to working with Team Schein to build on the strong foundation established by Stan while accelerating value creation.”
Before joining Thermo Fisher, Lowery held leadership roles at Maytag Corporation and General Motors. He earned a master’s degree in manufacturing management from Kettering University and a bachelor’s degree in mechanical engineering from Tennessee Technological University.
“I am very pleased to welcome Fred to Henry Schein. Beyond his extensive operational experience, he brings a leadership philosophy that reflects the values that have long defined our company,” said Stanley M. Bergman, chairman of the board. “Fred understands the critical role we play in supporting dental and medical practitioners, and he is exceptionally well equipped to lead Henry Schein into its next phase of growth.”
The company’s board highlighted the completion of a search process leading to the appointment.
“On behalf of the Board, I would like to thank Stan for his exceptional leadership and invaluable contributions over more than three decades,” said Phil Laskawy, lead director and chair of the nominating and governance committee at Henry Schein. “After a comprehensive search process, we are confident that Fred is the right successor to honor Henry Schein’s proud heritage. With extensive commercial, logistics, and manufacturing expertise, and a focus on customer satisfaction, he has the combination of experience and capabilities necessary to accelerate growth and value creation.”
Board members also commented on the anticipated transition.
“We are excited about our strategic partnership with Henry Schein and look forward to supporting the next chapter of the company’s journey under Fred’s leadership,” said Max Lin, board member and vice chair of the nominating and governance committee at Henry Schein and partner at KKR. “We believe Fred brings a unique combination of healthcare distribution experience, operational best practices, and accountable leadership that will accelerate our strategic initiatives and further differentiate Henry Schein as a world-class business.”
